Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
DOI:
https://doi.org/10.33448/rsd-v11i13.35082Keywords:
Highly Active Antiretroviral Therapy; Liver Cells; Drug response biomarkers.Abstract
Objective: to verify which antiretroviral treatment regimen was safer for people living with HIV, dolutegravir 50mg + lamivudine 300mg + tenofovir 300mg or efavirenz 600mg + lamivudine 300mg + tenofovir 300mg. For this, the following laboratory tests of liver function were analyzed: total, direct and indirect bilirubin, aspartate amino transferase, alanine amino transferase, gamma glutamyl transferase and alkaline phosphatase. Methodology: cohort study, with the follow-up of 234 people living with HIV and starting antiretroviral therapy in the city of Belo Horizonte, Minas Gerais, Brazil, with data collected between August 2015 and December 2018. Results: Mean values for the results of total and indirect bilirubin, aspartate amino transferase, alanine amino transferase and alkaline phosphatase tests reduced after 72 weeks for the two therapeutic regimens. The mean value for direct bilirubin in people taking efavirenz increased at 72 weeks and was above baseline compared to baseline. For gamma glutamyl transferase, the mean of the results was above the reference value in both groups before treatment. After 72 weeks of therapy with dolutegravir, the mean returned to baseline and, in the case of efavirenz, the mean remained high. Bonett's and Dunnett's tests had no statistical difference, indicating that the two therapeutic regimens are safe. Conclusions: the two therapeutic regimens studied proved to be safe and did not cause an increase in the variance for laboratory tests that were markers of liver function.
References
Agência Europeia De Medicamentos – EMA. (2012). Anexo I: resumo das características do medicamento – Efavirenz. https://ec.europa.eu/hea lth/documents/community- register/2012/20121025124790/anx_124790_pt.pdf.
Alghamdi, S., Alrbiaan, A., Alaraj, A., Alhuraiji, A., Alghamdi, M., & Alrajhi, A. (2016). Elevated alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection. Annals of Saudi Medicine, 36(4), 288–291. https://doi.org/10.5144/0256-4947.2016.288
Anyanwu, C. F., JohnBull, T. O., Usman, I. M., Aigbogun, E. O. J., Ochai, J., Qasem, A. H., Alkhayyat, S. S., Alexiou, A., & Batiha, G. E. S. (2021). Substance Use, Highly Active Antiretroviral Therapy, and Liver Enzymes: Evidence From a Cross-Sectional Study of HIV-Infected Adult Patients Without Comorbidities on HAART in the University of Port Harcourt Teaching Hospital. Frontier in Reproductive Health, 3(1), 1-12. https://doi.org/10.3389/frph.2021.664080
Brasil (2018). Protocolo Clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. Ministério da Saúde.
Brasil (2018a). Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Crianças e Adolescentes. Ministério da Saúde.
Cai, J., Osikowicz, M., & Sebastiani, G. (2019). Clinical significance of liver transaminases in HIV-infected patients. AIDS, 33(8), 1267–1282. https://doi.org/10.1097/QAD.0000000000002233
Chen, S., St Jean, P., Borland, J., Song, I., Yeo, A. J., Piscitelli, S., & Rubio, J. P. (2014). Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics, 15(1), 9-16. https://doi.org/10.2217/pgs.13.190
Cysne, A. C., Torga, E. D. G. C., Luzia, E. L., Lemos, L. M. C., Souza, L. M. S., Rocha, M. A. P., Siqueira, S. B., & Resende, S. E (2016). Manual de Exames Laboratoriais da rede SUS-BH. 1 ed. Prefeitura Municipal de Belo Horizonte.
Dusingize, J. C., Hoover, D. R., Shi, Q., Mutimura, E., Rudakemwa, E., Ndacyayisenga, V., Gakindi, L., Mulvihill, M., Sinayobye, J. D., Musabeyezu, E., & Anastos, K. (2015). Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. AIDS Research And Human Retroviruses, 31(7), 723–730. https://doi.org/10.1089/AID.2014.0170
Ejilemele, A. A., Nwauche, C. A., & Ejele, O. A. (2007). Pattern of abnormal liver enzymes in HIV patients presenting at a Nigerian Tertiary Hospital. The Nigerian Postgraduate Medical Journal, 14(4), 306–309. https://pubmed.ncbi.nlm.nih.gov/18163139/
Gebremicael, G., Tola, H. H., Gebreegziaxier, A., & Kassa, D. (2021). Incidence of Hepatotoxicity and Factors Associated During Highly Active Antiretroviral Therapy in People Living with HIV in Ethiopia: A Prospective Cohort Study. HIV/AIDS, 13(1), 329–336. https://doi.org/10.2147/HIV.S283076
Gil, A. C. M., Lorenzetti, R., Mendes, G. B., Morcillo, A. M., Toro, A. A. D. C., Silva, M. T. N. D., & Vilela, M. M. D. S. (2007). Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy. Sao Paulo Medical Journal, 125(1), 205-209.
Kalyesubula, R., Kagimu, M., Opio, K. C., Kiguba, R., Semitala, C. F., Schlech, W. F., & Katabira, E. T. (2011). Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. African Health Sciences, 11(1), 16–23. https://pubmed.ncbi.nlm.nih.gov/21572852/
Kimm, H., Kim, S., & Jee, S. H. (2010). The independent effects of cigarette smoking, alcohol consumption, and serum aspartate aminotransferase on the alanine aminotransferase ratio in korean men for the risk for esophageal cancer. Yonsei Medical Journal, 51(3), 310–317. https://doi.org/10.3349/ymj.2010.51.3.310
Kim, W. R., Flamm, S. L., Di Bisceglie, A. M., Bodenheimer, H. C., & Public Policy Committee of the American Association for the Study of Liver Disease (2008). Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology, 47(4), 1363–1370. https://doi.org/10.1002/hep.22109
Kontorinis, N., & Dieterich, D. (2003). Hepatotoxicity of antiretroviral therapy. AIDS Reviews, 5(1), 36–43. https://pubmed.ncbi.nlm.nih.gov/12875106/
Lucien, K., Clement, A., Fon, N., Weledji, P., & Ndikvu, C. (2010). The effects of antiretroviral treatment on liver function enzymes among HIV-infected out patients attending the central hospital of Yaounde, Cameroon. African Journal of Clinical and Experimental Microbiology, 11(3),174-178. https://doi.org/10.4314/ajcem.v11i3.57777
Martins, A. C. M., Oliveira, E. B., Roman, R (2020). TeleCondutas: HIV: acompanhamento e tratamento de pessoas vivendo com HIV/AIDS na Atenção Primária à Saúde: versão digital 2020. Universidade Federal do Rio Grande do Sul. https://www.ufrgs.br/telessauders/teleconsultoria/0800-644-6543/#telecondutas-0800.
Mata-Marín, J. A., Gaytán-Martínez, J., Grados-Chavarría, B. H., Fuentes-Allen, J. L., Arroyo-Anduiza, C. I., & Alfaro-Mejía, A. (2009). Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study. Virology Journal, 6(1),1-4. https://doi.org/10.1186/1743-422X-6-181
Mendes, J. C., Bonolo, P. F., Ceccato, M., Costa, J. O., Reis, A., Dos Santos, H., & Silveira, M. R. (2018). Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy. European journal of clinical pharmacology, 74(8), 1077–1088. https://doi.org/10.1007/s00228-018-2472-y
Minas Gerais (2018). Boletim epidemiológico mineiro: análise epidemiológica de HIV/aids. Panorama do ano de 2017. Secretaria Estadual de Saúde.
Mulu, W., Gidey, B., Chernet, A., Alem, G., & Abera, B. (2013). Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiopian Journal of Health Sciences, 23(3), 217–226. https://doi.org/10.4314/ejhs.v23i3.4
Oikonomou, K. G., Tsai, E., Sarpel, D., & Dieterich, D. T. (2019). Liver Disease in Human Immunodeficiency Virus Infection. Clinics in Liver Disease, 23(2), 309–329. https://doi.org/10.1016/j.cld.2018.12.011
Otto, A. O., Rivera, C. G., Zeuli, J. D., & Temesgen, Z. (2021). Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells, 10(5), 1-21. https://doi.org/10.3390/cells10051263
Park, E. Y., Lim, M. K., Oh, J. K., Cho, H., Bae, M. J., Yun, E. H., Kim, D. I., & Shin, H. R. (2013). Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PloS One, 8(5), e63439. https://doi.org/10.1371/journal.pone.0063439
Segamwenge, I. L., & Bernard, M. K. (2018). Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy. Case Reports in Hepatology, 2018(1), 1-5. https://doi.org/10.1155/2018/1270716
Silva, K. M. M.; Neves, R. A.; & Costa, S. H. N. (2021). Prevalência de alterações da gama-glutamil transferase e hematológicas em indivíduos que relataram uso de álcool. Revista Brasileira Militar de Ciências. 7(17), 23-30. https://rbmc.emnuvens.com.br/rbmc/article/view/86/53
Shiferaw, M. B., Tulu, K. T., Zegeye, A. M., & Wubante, A. A. (2016). Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study. AIDS Research and Treatment, 2016, 1985452. https://doi.org/10.1155/2016/1985452
Teixeira, L. S., Ceccato, M. G. B., Carvalho, W. S., Costa, J. O., Bonolo, F. P., Mendes, J. C., & Silveira, M. R. (2020). Prevalência e fatores associados ao tabagismo em pessoas vivendo com HIV em tratamento. Revista de Saúde Pública, 54(1), 01-13. https://doi.org/10.11606/s1518-8787.2020054001828
Telli, E. M. R. P.; Frigeri, M.; & Mello, S. R. (2016). Avaliação da atividade de enzimas hepáticas em dependentes, ex-dependentes e não usuários do etanol. Revista Brasileira de Análises Clínicas. Santa Catarina, 48(3), 245-52.
Tesfa, E., Siefu, D., Belayneh, Y., & Mekonnen, Z. (2019). Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia. BMC Research Notes, 12(1), 714. https://doi.org/10.1186/s13104-019-4748-4
Wannamethee, S. G., & Shaper, A. G. (2010). Cigarette smoking and serum liver enzymes: the role of alcohol and inflammation. Annals of clinical biochemistry, 47(4), 321–326. https://doi.org/10.1258/acb.2010.009303
Woldu, M. A., Getaneh, H. D., Lenjisa, J. L., Tegegn, G. T., Umeta, G. T., & Ayano, H. D. (2014). The Risk of Hepatotoxicity Associated with HAART/Anti-Tb Co-Treatment: A Case Control Study in a Central Ethiopian Referral Hospital. Family Medicine and Medical Science Research, 3(3), 1-6. http://dx.doi.org/10.4172/2327-4972.1000129
Wood, S., Byrne, M., Deiss, R., Okulicz, J., O’Bryan, T., Schofield, C., & Ganesan, A. (2017). The incidence and risk factors associated with chronic liver enzyme elevation (cLEE) in HIV-monoinfected persons. In Open Forum Infectious Diseases, 4(1), 220-221. https://doi.org/10.1093/ofid/ofx163.450
Wood, S., Won, S. H., Hsieh, H. C., Lalani, T., Kronmann, K., Maves, R. C., Utz, G., Schofield, C., Colombo, R. E., Okulicz, J. F., Blaylock, J., Agan, B. K., & Ganesan, A. (2021). Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era. Open Forum Infectious Diseases, 8(3), ofab076. https://doi.org/10.1093/ofid/ofab076
Wu, P. Y., Cheng, C. Y., Liu, C. E., Lee, Y. C., Yang, C. J., Tsai, M. S., Cheng, S. H., Lin, S. P., Lin, D. Y., Wang, N. C., Lee, Y. C., Sun, H. Y., Tang, H. J., & Hung, C. C. (2017). Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PloS One, 12(2), e0171596. https://doi.org/10.1371/journal.pone.0171596
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Jorgino Julio Cesar; Micheline Rosa Silveira; Paulo Roberto Maia; Cléssius Ribeiro de Souza; Henrique Pereira de Aguilar Penido; Ana Cristina da Silva Fernandes; Maria das Graças Braga Ceccato
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
